publication venue for
- Development and external validation of a breast cancer absolute risk prediction model in Chinese population. 23:62. 2021
- Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. 20:38. 2018
- Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. 20:59. 2018
- Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. 19:76. 2017
- Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. 18:1. 2016
- Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. 18:110. 2016
- Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. 18:15. 2016
- Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. 17:56. 2015
- Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. 16:3419. 2014
- Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. 16:R8. 2014
- Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort. 15:R71. 2013
- Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. 15:R46. 2013
- Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. 14:R42. 2012
- Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?. 12:S18. 2010
- Tailored targeted therapy for all: a realistic and worthwhile objective against. 11:S8. 2009
- Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?. 10:S23. 2008
- Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. 7:R661-R668. 2005
- Clinical trial update: National Cancer Institute of Canada. 7:48-51. 2005
- Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women. 7:70-76. 2005
- S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situof the breast. 6:R308-R315. 2004
- Mammographic density is related to stroma and stromal proteoglycan expression. 5:R129-R135. 2003
- A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. 6:R8-R17. 2003
- Characterising breast tissue for the development of a tissue-equivalent phantom. 2:a43. 2000
- Mutant p53 exerts its gain of function through activation of the NF-κB pathway 2005